Hospital-Made cancer fighters: new CAR-T trial for leukemia

NCT ID NCT07371403

First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times

Summary

This study is testing whether a personalized cell therapy called MB-CART19.1 can be manufactured right at the hospital for children and adults with B-cell acute lymphoblastic leukemia that has come back or not responded to standard treatments. The therapy uses the patient's own immune cells, which are collected, modified to target cancer cells, and then infused back. The main goal is to see if the cells can be made successfully on-site, with a secondary look at how well they work.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
MB-CART19.1 (a type of CAR-T cell therapy made from the patient's own immune cells)
What this could lead to
If successful, this could show that making CAR-T cells at the hospital is possible, potentially offering a faster and more accessible treatment for patients with relapsed or refractory B-ALL.
What could go wrong
This is a very small, early feasibility study with only 12 participants. It focuses on whether the cells can be made, not yet on how well they work. The therapy may not be effective or could cause serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • King Hussein Cancer Center

    RECRUITING

    Amman, 11941, Jordan

More trials for these conditions

Other studies related to the condition(s) this trial covers.